134 related articles for article (PubMed ID: 34937474)
1. Roles of Dclk1 in the pathogenesis, diagnosis, prognosis and treatment of pancreatic cancer: A review.
Wang Y; Yi J; Liu X
Expert Rev Gastroenterol Hepatol; 2022 Jan; 16(1):13-19. PubMed ID: 34937474
[TBL] [Abstract][Full Text] [Related]
2. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.
Ito H; Tanaka S; Akiyama Y; Shimada S; Adikrisna R; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Yamaoka S; Tanabe M
PLoS One; 2016; 11(1):e0146564. PubMed ID: 26764906
[TBL] [Abstract][Full Text] [Related]
3. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1.
Zhou B; Sun C; Hu X; Zhan H; Zou H; Feng Y; Qiu F; Zhang S; Wu L; Zhang B
Cell Physiol Biochem; 2017; 44(5):1867-1881. PubMed ID: 29224010
[TBL] [Abstract][Full Text] [Related]
5. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis.
Westphalen CB; Takemoto Y; Tanaka T; Macchini M; Jiang Z; Renz BW; Chen X; Ormanns S; Nagar K; Tailor Y; May R; Cho Y; Asfaha S; Worthley DL; Hayakawa Y; Urbanska AM; Quante M; Reichert M; Broyde J; Subramaniam PS; Remotti H; Su GH; Rustgi AK; Friedman RA; Honig B; Califano A; Houchen CW; Olive KP; Wang TC
Cell Stem Cell; 2016 Apr; 18(4):441-55. PubMed ID: 27058937
[TBL] [Abstract][Full Text] [Related]
6. DCLK1 and its oncogenic functions: A promising therapeutic target for cancers.
Ye L; Liu B; Huang J; Zhao X; Wang Y; Xu Y; Wang S
Life Sci; 2024 Jan; 336():122294. PubMed ID: 38007147
[TBL] [Abstract][Full Text] [Related]
7. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
[TBL] [Abstract][Full Text] [Related]
8. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma.
Nishio K; Kimura K; Amano R; Nakata B; Yamazoe S; Ohira G; Miura K; Kametani N; Tanaka H; Muguruma K; Hirakawa K; Ohira M
World J Gastroenterol; 2017 Aug; 23(31):5764-5772. PubMed ID: 28883702
[TBL] [Abstract][Full Text] [Related]
9. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
[TBL] [Abstract][Full Text] [Related]
10. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
11. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
Gao T; Wang M; Xu L; Wen T; Liu J; An G
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
[TBL] [Abstract][Full Text] [Related]
12. DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.
Ge Y; Fan X; Huang X; Weygant N; Xiao Z; Yan R; Liu H; Liu J; An G; Yao J
Mol Cancer Res; 2021 Dec; 19(12):1980-1991. PubMed ID: 34610960
[TBL] [Abstract][Full Text] [Related]
13. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
[TBL] [Abstract][Full Text] [Related]
14. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel DCLK1 inhibitor containing purine skeleton for the treatment of pancreatic cancer.
Chen Y; Meng L; Wang W; Ye L; Huang L; Wang C; Wang S; Li M; Pei Y; Zhang S; Zou Y; Xu Y
Eur J Med Chem; 2023 Dec; 261():115846. PubMed ID: 37862816
[TBL] [Abstract][Full Text] [Related]
16. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
17. Functional implication of Dclk1 and Dclk1-expressing cells in cancer.
Westphalen CB; Quante M; Wang TC
Small GTPases; 2017 Jul; 8(3):164-171. PubMed ID: 27458755
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.
Carli ALE; Afshar-Sterle S; Rai A; Fang H; O'Keefe R; Tse J; Ferguson FM; Gray NS; Ernst M; Greening DW; Buchert M
Proteomics; 2021 Jul; 21(13-14):e2000098. PubMed ID: 33991177
[TBL] [Abstract][Full Text] [Related]
19. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer.
Wang J; Wang S; Zhou J; Qian Q
Biomed Pharmacother; 2018 Jun; 102():147-152. PubMed ID: 29550638
[TBL] [Abstract][Full Text] [Related]
20. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
